Product news

Go to navigation
Go to content

The following shows headlines of all product-related news articles published within 12-months, starting from most recent.

Subscribe to RSS news feed

Pages
1
2
Next

- Jul 1, 2008
- Summary Judgment granted for SEROQUEL® patent litigation
- Jun 4, 2008
- AstraZeneca submits an sNDA for SYMBICORT® for the treatment of asthma in children as young as age six
- May 30, 2008
- AstraZeneca submits sNDA for NEXIUM® I.V. for peptic ulcer bleed indication
- May 20, 2008
- Study analyzed SYMBICORT® in children with persistent asthma
- May 20, 2008
- New patient satisfaction study with budesonide/formoterol combination therapy and fluticasone/salmeterol combination therapy in adults with asthma
- May 14, 2008
- FDA approves AstraZeneca’s SEROQUEL® for maintenance treatment in bipolar disorder
- May 8, 2008
- AstraZeneca submits sNDA for SEROQUEL XR™ for the treatment of generalized anxiety disorder – a first for the atypical antipsychotic class of medicines
- May 5, 2008
- New data on SEROQUEL XR™ in treatment of both major depressive disorder and generalized anxiety disorder presented at APA Annual Meeting
- Apr 30, 2008
- AstraZeneca submits an sNDA for SYMBICORT® for COPD indication
- Apr 15, 2008
- AstraZeneca settles US NEXIUM® patent litigation with Ranbaxy
- Mar 18, 2008
- Study compares bronchodilatory effects of SYMBICORT® and ADVAIR® in adults with asthma
- Mar 17, 2008
- Study analyzed long-term SYMBICORT® use in children with persistent asthma
- Feb 29, 2008
- AstraZeneca submits sNDA for SEROQUEL XR™ for the treatment of major depressive disorder
- Feb 28, 2008
- FDA approves NEXIUM® for the treatment of short-term GERD in children 1 To 11 years old
- Jan 2, 2008
- AstraZeneca submits sNDAs for SEROQUEL XR™ for the treatment of bipolar mania and bipolar depression
- Dec 14, 2007
- Data show ARIMIDEX® (anastrozole) continues to be superior to Tamoxifen in helping reduce the risk of recurrence in patients with early breast cancer
- Dec 10, 2007
- FDA concludes there is no increased risk of cardiac events for patients treated with omeprazole and NEXIUM® (esomeprazole magnesium).
- Nov 29, 2007
- AstraZeneca receives six months pediatric exclusivity patent extension for ARIMIDEX® (anastrozole) from the FDA
- Nov 16, 2007
- SEROQUEL XR™ receives approval from FDA for maintenance treatment of schizophrenia
- Nov 9, 2007
- CRESTOR® now indicated to slow the progression of atherosclerosis in patients with elevated cholesterol

Pages
1
2
Next

Page tools

Who is AstraZeneca?

Watch this short video to learn who we are and what we do